LAG3 showed a protective effect in AML, ovarian cancer, and breast cancer, while in bladder cancer (transitional cell carcinoma) and breast and brain cancer (glioma), it presented an adverse prognostic role. Here, LAG3 is linked to urinary bladder carcinoma.